How to buy RedHill Biopharma stock | $4.89

RedHill Biopharma Ltd is a drug manufacturers-specialty & generic business based in the US. RedHill Biopharma shares (RDHL) are listed on the NASDAQ and all prices are listed in US Dollars. RedHill Biopharma employs 182 staff and has a trailing 12-month revenue of around 0.00.

RedHill Biopharma stock price (NASDAQ: RDHL)

Use our graph to track the performance of RDHL stocks over time.

RedHill Biopharma shares at a glance

• Key figures

Information last updated 2021-09-12.

Latest market close	$4.89
52-week range	$5.90 - $11.52
50-day moving average	$7.59
200-day moving average	$7.23
Wall St. target price	$19.94
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.31

Buy RedHill Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy RedHill Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

RedHill Biopharma price performance over time

Historical closes compared with the close of $4.89 from 2021-09-17

1 week (2021-09-10)	-39.48%
1 month (2021-08-18)	-28.61%
3 months (2021-06-18)	-29.84%
6 months (2021-03-19)	-34.97%

1 year (2020-09-18)	-53.69%
2 years (2019-09-18)	-35.91%
3 years (2018-09-18)	8
5 years (2016-09-16)	14.6297

RedHill Biopharma financials

Revenue TTM	$84.5 million
Gross profit TTM	$28.3 million
Return on assets TTM	-25.81%
Return on equity TTM	-295.96%
Profit margin	-112.4%
Book value	$0.63
Market capitalisation	$377.5 million

TTM: trailing 12 months

Shorting RedHill Biopharma shares

There are currently 1.8 million RedHill Biopharma shares held short by investors – that's known as RedHill Biopharma's "short interest". This figure is 8.7% down from 2.0 million last month.

There are a few different ways that this level of interest in shorting RedHill Biopharma shares can be evaluated.

RedHill Biopharma's "short interest ratio" (SIR)

RedHill Biopharma's "short interest ratio" (SIR) is the quantity of RedHill Biopharma shares currently shorted divided by the average quantity of RedHill Biopharma shares traded daily (recently around 293962.48012719). RedHill Biopharma's SIR currently stands at 6.29. In other words for every 100,000 RedHill Biopharma shares traded daily on the market, roughly 6290 shares are currently held short.

However RedHill Biopharma's short interest can also be evaluated against the total number of RedHill Biopharma shares, or, against the total number of tradable RedHill Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case RedHill Biopharma's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 RedHill Biopharma shares in existence, roughly 40 shares are currently held short) or 0.0593% of the tradable shares (for every 100,000 tradable RedHill Biopharma shares, roughly 59 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against RedHill Biopharma.

Find out more about how you can short RedHill Biopharma stock.

RedHill Biopharma share dividends

We're not expecting RedHill Biopharma to pay a dividend over the next 12 months.

RedHill Biopharma share price volatility

Over the last 12 months, RedHill Biopharma's shares have ranged in value from as little as $5.9 up to $11.52. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while RedHill Biopharma's is 1.3975. This would suggest that RedHill Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

RedHill Biopharma overview

RedHill Biopharma Ltd. , a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. .

Frequently asked questions

What percentage of RedHill Biopharma is owned by institutions?
Currently 18.389% of RedHill Biopharma shares are held by institutions. How many people work for RedHill Biopharma?
Latest data suggests 182 work at RedHill Biopharma. When does the fiscal year end for RedHill Biopharma?
RedHill Biopharma's fiscal year ends in December. Where is RedHill Biopharma based?
RedHill Biopharma's address is: 21 Ha?arba?a Street, Tel Aviv, Israel, 6473921 What is RedHill Biopharma's ISIN number?
RedHill Biopharma's international securities identification number is: US7574681034 What is RedHill Biopharma's CUSIP number?
RedHill Biopharma's Committee on Uniform Securities Identification Procedures number is: 757468103